The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
about
Leukotrienes, mast cells, and T cellsAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewCD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective studyInterference with immune-cell-mediated bone resorption in periodontal disease.Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21.Abatacept for the treatment of rheumatoid arthritis: A review.Can bone loss in rheumatoid arthritis be prevented?Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis.Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
P2860
Q24795112-6D60E032-82F0-4622-B10C-2C5E91C96928Q26774874-4D38DB70-89BF-4479-8F02-6D804F3DAD8DQ35675258-F1A1FC8A-7DD5-43B7-A89A-53041B8515E3Q35986133-17A37A9E-1962-4B10-938F-13F342EC7037Q36281132-46C8C3F0-98A1-4B33-9A6F-64DBB1401CB1Q36938527-77358D9C-DD2A-4567-B5B5-138BA0D58872Q37106639-7C0952B6-F68C-4F2E-8A21-B9A3107AE653Q37639837-27162135-353D-46C2-B5D4-346E2BB8D094Q37672814-5175CD96-7CFD-46FB-A490-01334FC5F9A1Q38115190-E94745F5-AD65-4B7E-A10B-27AC278C4628Q38170177-3421A4B7-799F-4056-9F96-104E2B4CB9AEQ38222449-E3A0A546-E8D0-48F8-A91B-201DB36C97A3Q48219239-46BC2BAA-09FA-477D-B77F-ED007E861347
P2860
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@ast
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en-gb
type
label
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@ast
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en-gb
prefLabel
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@ast
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en-gb
P2860
P1476
The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
@en
P2860
P304
P356
10.1517/13543784.12.4.673
P407
P50
P577
2003-04-01T00:00:00Z